FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114553148> ?p ?o ?g. }

• W2114553148 endingPage "4182" @default.
• W2114553148 startingPage "4173" @default.
• W2114553148 abstract "Abstract Purpose: The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers. Experimental Design: This was a phase I, open-label, dose-escalation study. Drug was administered orally once per day either on an intermittent (arm 1; days 1–5 and 8–12 of a 28-day cycle) or continuous (arm 2; days 1–28 of a 28-day cycle) schedule. Additional patients were treated at the arm 2 MTD in a food effects substudy. Results: Eighty-four patients were treated in the arm 1 (n = 51), arm 2 (n = 20), and food effects (n = 13) cohorts. The most frequent study drug–related adverse events were gastrointestinal disorders (69.0%), with diarrhea being the most common (48.8%). The MTD was 12 and 8 mg for arm 1 and 2, respectively. The dose-limiting toxicities (DLT) consisted of grade III diarrhea (n = 3) and grade III elevated aspartate aminotransferase (AST; n = 1). The pharmacokinetics profile was dose proportional, with no evidence of drug accumulation. PX-866–associated inhibition of platelet pAKTSER473 was observed at the arm 2 MTD. The best response per Response Evaluation Criteria in Solid Tumors (RECIST) was stable disease in 22% of evaluable patients in arm 1, 53% in arm 2, and 11% in the food effects cohort. Eight patients were on study for 4 or more months. Conclusions: This first-in-human study shows that PX-866, an irreversible small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K), was well tolerated and was associated with prolonged stable disease, particularly when using a continuous dosing schedule. Clin Cancer Res; 18(15); 4173–82. ©2012 AACR." @default.
• W2114553148 created "2016-06-24" @default.
• W2114553148 creator A5003463083 @default.
• W2114553148 creator A5007992309 @default.
• W2114553148 creator A5008593691 @default.
• W2114553148 creator A5026095888 @default.
• W2114553148 creator A5029892731 @default.
• W2114553148 creator A5030273391 @default.
• W2114553148 creator A5033878540 @default.
• W2114553148 creator A5037102866 @default.
• W2114553148 creator A5041718551 @default.
• W2114553148 creator A5053481267 @default.
• W2114553148 creator A5069777765 @default.
• W2114553148 creator A5078259926 @default.
• W2114553148 creator A5088419169 @default.
• W2114553148 creator A5090647064 @default.
• W2114553148 date "2012-07-30" @default.
• W2114553148 modified "2023-09-26" @default.
• W2114553148 title "A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors" @default.
• W2114553148 cites W1594020010 @default.
• W2114553148 cites W1964578073 @default.
• W2114553148 cites W1977267072 @default.
• W2114553148 cites W1981711832 @default.
• W2114553148 cites W1984418041 @default.
• W2114553148 cites W1991384876 @default.
• W2114553148 cites W1999065747 @default.
• W2114553148 cites W2002457274 @default.
• W2114553148 cites W2004637409 @default.
• W2114553148 cites W2006771504 @default.
• W2114553148 cites W2008906394 @default.
• W2114553148 cites W2012306540 @default.
• W2114553148 cites W2014096417 @default.
• W2114553148 cites W2025183726 @default.
• W2114553148 cites W2031594903 @default.
• W2114553148 cites W2037253872 @default.
• W2114553148 cites W2039343159 @default.
• W2114553148 cites W2057823750 @default.
• W2114553148 cites W2062312459 @default.
• W2114553148 cites W2070765493 @default.
• W2114553148 cites W2073308507 @default.
• W2114553148 cites W2094079572 @default.
• W2114553148 cites W2101549875 @default.
• W2114553148 cites W2102839088 @default.
• W2114553148 cites W2118073504 @default.
• W2114553148 cites W2119855881 @default.
• W2114553148 cites W2120943945 @default.
• W2114553148 cites W2129172946 @default.
• W2114553148 cites W2139248078 @default.
• W2114553148 cites W2139712038 @default.
• W2114553148 cites W2141134269 @default.
• W2114553148 cites W2162584257 @default.
• W2114553148 cites W2164158840 @default.
• W2114553148 cites W2165404212 @default.
• W2114553148 cites W2167997534 @default.
• W2114553148 cites W2168270349 @default.
• W2114553148 cites W2169661783 @default.
• W2114553148 cites W2318897085 @default.
• W2114553148 cites W2570436914 @default.
• W2114553148 doi "https://doi.org/10.1158/1078-0432.ccr-12-0714" @default.
• W2114553148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22693357" @default.
• W2114553148 hasPublicationYear "2012" @default.
• W2114553148 type Work @default.
• W2114553148 sameAs 2114553148 @default.
• W2114553148 citedByCount "146" @default.
• W2114553148 countsByYear W21145531482012 @default.
• W2114553148 countsByYear W21145531482013 @default.
• W2114553148 countsByYear W21145531482014 @default.
• W2114553148 countsByYear W21145531482015 @default.
• W2114553148 countsByYear W21145531482016 @default.
• W2114553148 countsByYear W21145531482017 @default.
• W2114553148 countsByYear W21145531482018 @default.
• W2114553148 countsByYear W21145531482019 @default.
• W2114553148 countsByYear W21145531482020 @default.
• W2114553148 countsByYear W21145531482021 @default.
• W2114553148 countsByYear W21145531482022 @default.
• W2114553148 countsByYear W21145531482023 @default.
• W2114553148 crossrefType "journal-article" @default.
• W2114553148 hasAuthorship W2114553148A5003463083 @default.
• W2114553148 hasAuthorship W2114553148A5007992309 @default.
• W2114553148 hasAuthorship W2114553148A5008593691 @default.
• W2114553148 hasAuthorship W2114553148A5026095888 @default.
• W2114553148 hasAuthorship W2114553148A5029892731 @default.
• W2114553148 hasAuthorship W2114553148A5030273391 @default.
• W2114553148 hasAuthorship W2114553148A5033878540 @default.
• W2114553148 hasAuthorship W2114553148A5037102866 @default.
• W2114553148 hasAuthorship W2114553148A5041718551 @default.
• W2114553148 hasAuthorship W2114553148A5053481267 @default.
• W2114553148 hasAuthorship W2114553148A5069777765 @default.
• W2114553148 hasAuthorship W2114553148A5078259926 @default.
• W2114553148 hasAuthorship W2114553148A5088419169 @default.
• W2114553148 hasAuthorship W2114553148A5090647064 @default.
• W2114553148 hasConcept C111113717 @default.
• W2114553148 hasConcept C112705442 @default.
• W2114553148 hasConcept C126322002 @default.
• W2114553148 hasConcept C141071460 @default.
• W2114553148 hasConcept C197934379 @default.
• W2114553148 hasConcept C2776694085 @default.
• W2114553148 hasConcept C2779984678 @default.

• next